Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hewlett Packard Enterprise Co (HPE) vs Heron Therapeutics Inc (HRTX) Price & Performance

Hewlett Packard Enterprise CoTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Hewlett Packard Enterprise Co vs Heron Therapeutics Inc — how do they compare? Hewlett Packard Enterprise Co trades at $57.01 (market cap $72.01B), while Heron Therapeutics Inc trades at $0.35 (market cap $61.47M). The key difference: Hewlett Packard Enterprise Co is far larger — about 1171.5× Heron Therapeutics Inc's market cap, and Hewlett Packard Enterprise Co pays a 1.05% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

HPEHRTX
Market Cap
$72.01B$61.47M
Sector
TechnologyHealth
52-Week High
$56.14$1.49
52-Week Low
$20.01$0.32
Enterprise Value
$87.96B$168.21M
Dividend Yield
1.05%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hewlett Packard Enterprise Co

HPE stock trades at $56.32, up 3.02% with strong momentum following recent analyst upgrades. The company shows robust earnings beats in recent quarters with Q1 2026 EPS of $0.79 beating expectations of $0.535. Technical indicators suggest bullish momentum while fundamentals show revenue growth to $34.3B in 2025, though net income declined significantly to $57M. Recent Morgan Stanley upgrade highlights AI infrastructure strength.

Outlook remains positive with AI-driven growth potential, though elevated P/E ratio of 50.82 warrants caution. Key risks include competitive pressures in server markets and execution challenges. Analyst consensus price target of $69.81 offers 24% upside potential from current levels, supported by institutional buying interest.

Heron Therapeutics Inc

HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.

The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Hewlett Packard Enterprise Co

Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.

Read more on HPE

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX